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Abstract
The pathogenesis of Plasmodium falciparum malaria is linked to the variant surface antigen
PfEMP1, which mediates tethering of infected erythrocytes to the host endothelium and is
encoded by approximately 60 var genes per parasite genome. Repeated episodes of
malaria infection result in the gradual acquisition of protective antibodies against PfEMP1
variants. The antibody repertoire is believed to provide a selective pressure driving the
clonal expansion of parasites expressing unrecognized PfEMP1 variants, however, due to
the lack of experimental in vivo models there is only limited experimental evidence in support
of this concept. To get insight into the impact of naturally acquired immunity on the
expressed var gene repertoire early during infection we performed controlled human malaria
infections of 20 adult African volunteers with life-long malaria exposure using aseptic, puri-
fied, cryopreserved P. falciparum sporozoites (Sanaria PfSPZ Challenge) and correlated
serological data with var gene expression patterns from ex vivo parasites. Among the 10
African volunteers who developed patent infections, individuals with low antibody levels
showed a steep rise in parasitemia accompanied by broad activation of multiple, predomi-
nantly subtelomeric var genes, similar to what we previously observed in naïve volunteers.
In contrast, individuals with intermediate antibody levels developed asymptomatic infections
and the ex vivo parasite populations expressed only few var gene variants, indicative of
clonal selection. Importantly, in contrast to parasites from naïve volunteers, expression of
var genes coding for endothelial protein C receptor (EPCR)-binding PfEMP1 that are
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volunteers. Moreover, we followed var gene expression for up to six parasite replication
cycles and demonstrated for the first time in vivo a shift in the dominant var gene variant. In
conclusion, our data suggest that P. falciparum activates multiple subtelomeric var genes at
the onset of blood stage infection facilitating rapid expansion of parasite clones which
express PfEMP1 variants unrecognized by the host’s immune system, thus promoting over-
all parasite survival in the face of host immunity.
Author summary
Parasites of the species Plasmodium falciparum are responsible for the most severe form
of malaria, particularly affecting children under the age of five years, and escape from the
human immune response by antigenic variation. This is achieved by alteration of the host
cell surface exposed protein PfEMP1, which tethers infected erythrocytes to the endothe-
lium. Gaining knowledge about P. falciparum var gene expression in vivo remains essen-
tial to understanding pathogenesis and immunity in humans. We can show that at the
onset of the blood stage in malaria-naïve hosts the parasite population activates a large
group of var genes simultaneously, but in individuals with high levels of naturally
acquired immunity the var transcript pattern was narrowed to a single or very few
PfEMP1 variants compatible with parasite survival in the face of host immunity. Expres-
sion of PfEMP1 variants associated with a particular receptor binding phenotype com-
monly observed in parasites causing severe malaria was absent in parasites recovered
from infected individuals with prior exposure to malaria. These findings are of particular
importance for our understanding of the strategy of malaria parasites to establish and
maintain infections in the human host. They could not be characterized by the use of in
vitro cultures.
Introduction
The virulence of the malaria parasite Plasmodium falciparum has been linked to the ability of
infected erythrocytes to adhere to a range of cell surface molecules expressed on the vascular
endothelium. This phenomenon, known as sequestration, prevents the passage of infected
erythrocytes through the spleen, which would otherwise remove the infected erythrocytes
from the circulation and kill the parasites [1]. Sequestration is mediated by parasite proteins
that are exported to the erythrocyte surface where they are exposed to the host’s immune
system and induce variant-specific, anti-parasitic immune responses. P. falciparum possesses
several multi-copy gene families coding for variant surface antigens (VSAs), which are charac-
terized by extensive sequence polymorphisms. Members of the best-known VSA, the P. falcip-
arum erythrocyte membrane protein 1 (PfEMP1) family, mediate adhesion of infected
erythrocytes to the vascular endothelium through their affinity for different host receptors
including CD36, endothelial protein C receptor (EPCR) or placental chondroitin sulfate A
(CSA) [2, 3]. Only a single PfEMP1 variant is usually synthesized in each parasite. The long,
variable, extracellular PfEMP1 region responsible for receptor binding contains an N-terminal
segment (NTS) and a variable number of different Duffy-binding like (DBL classes α-z and
pam) and cysteine-rich inter-domain region (CIDR classes α-δ and pam) domains [4]. Nearly
all PfEMP1 have a semi-conserved N-terminal head structure consisting of an NTS and a
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DBLα-CIDR tandem domain [5]. Different types of the N-terminal CIDR domains confer
mutually exclusive receptor binding phenotypes [6]. CIDRα1 domains, with the exception of
those found in the var1 pseudogene, bind EPCR [7] and this interaction has been linked in
particular to cerebral malaria [8, 9]. CIDRα2–6 domains mediate CD36-binding [10], the
most commonly observed binding phenotype. The ligands of the N-terminal CIDRδ and the
more diverse CIDRβ and -γ domains are unknown, although an association with rosetting has
been suggested [11–14]. The atypical PfEMP1 variant VAR2CSA does not contain CIDR
domains and binds placental CSA through its DBL domains [15].
Each parasite isolate’s repertoire of PfEMP1 comprises a similar distribution of these mutu-
ally exclusive binding phenotypes, and this phenomenon can be explained through the ordered
genetic organization of the var genes. Thus PfEMP1 molecules have been grouped into four
categories (A, B, C and E) according to the protein domain composition as well as the type of
5’ upstream sequence (UPSA-E), chromosomal localization, and direction of transcription of
their encoding var genes [16–18]. Subtelomeric group A var genes encode PfEMP1 with
CIDRα1 or CIDRβ/γ/δ domains whereas telomeric group B and centromeric group C var
genes encode PfEMP1 with CD36-binding CIDRα2–6 domains. Recombination events have
translocated a set of UPSB var genes to the subtelomere (group B/A) or centromere (group
B/C). Group E describes the subtelomeric var2csa genes.
The P. falciparum reference strain NF54 encodes nine different group A PfEMP1 including
three predicted to bind EPCR and six with unknown binding properties of which three have
CIDRβ/γ/δ domains and three are copies without a CIDR domain (VAR3). In addition, NF54
has one copy of the var1 pseudogene. NF54 further encodes 37 group B PfEMP1, of which two
are B/A-type PfEMP1, binding EPCR via their CIDRα1 domains, and 35 are predicted to bind
CD36. Finally, the parasite encodes 13 group C PfEMP1 predicted to bind CD36, and one
VAR2CSA protein [4].
Expression of specific subsets of var genes has been linked to the clinical outcomes of
malaria. Initial observations indicated that group A var gene expression correlates with severe
forms of malaria in non-immune children, whereas group C var gene expression may be asso-
ciated with mild malaria [19–25]. Expression of group B var genes has been associated with
both severe and mild malaria cases [19, 20, 26–28]. These findings are in line with recent
observations that only A- and B-type var genes coding for EPCR-binding proteins are more
abundantly expressed during severe malaria [8, 9, 29–31]. A-type var genes are evolutionary
more conserved whereas B- and C-type var genes are more diverse and also more abundant in
the parasite genome. In accordance with their prevalent transcription in young children and
their conservation, antibodies against A- and B/A-type PfEMP1 proteins are rapidly acquired
early in life and before antibodies to B- and C-type PfEMP1 [32–36].
Most studies so far have investigated var gene expression from clinical isolates with
unknown var gene repertoires and without knowledge of the history of the infection. These
cross-sectional studies are very valuable for understanding the relationship between clinical
malaria and certain PfEMP1 types, but are limited with regards to explaining parasite strategies
to establish infection in a new host after transmission. To understand the hierarchies in var
gene expression in first-time infected individuals, we previously analyzed ex vivo var gene
expression profiles in 18 non-immune volunteers infected with aseptic, purified, cryopreserved
NF54 sporozoites (Sanaria PfSPZ Challenge (NF54)) [37]. All samples showed a remarkably
conserved, uniform expression pattern. Although most var gene variants were detectable at the
onset of the blood stage infection in each volunteer, transcription was predominantly from the
subtelomeric located var gene groups A, B and the intermediate group B/A. In contrast,
expression of the centrally located group C and B/C as well as of the three least polymorphic
var gene sub-families var1, var2csa and var3 was low or undetectable [37]. Interestingly, this
var expression in semi-immune volunteers
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pattern differed significantly from the NF54 culture that was used to generate the PfSPZ Chal-
lenge for these volunteer infections by mosquito passage. In this culture, the conserved var2csa
gene was predominantly transcribed [37, 38]. These observations suggest that var transcription
is reset during mosquito or liver passage, and at the early onset of P. falciparum blood infec-
tions an intrinsic var expression program determines the higher probability for expression of
A- and B-type PfEMP1 in naïve individuals [37].
In the present study, we investigated for the first time in vivo in a defined setting using
NF54 parasites how naturally acquired immunity to P. falciparum affects var gene expression
patterns early in infection. To this end, we analyzed the var transcript profiles of parasites iso-
lated from lifelong malaria-exposed adults participating in a controlled human malaria infec-
tion (CHMI) study of PfSPZ Challenge in Gabon [39] and compared the observed patterns to
the data set from malaria-naïve volunteers. We found that the var expression pattern at the
onset of infection depended on the degree of immunity to P. falciparum. Parasites from life-
long malaria-exposed volunteers who developed malaria symptoms and had low levels of anti-
bodies to various P. falciparum antigens showed a similar broad expression of subtelomeric B-
type var genes as malaria-naïve individuals, although less A-type var genes were expressed. In
contrast, parasites from asymptomatic volunteers who controlled parasitemia over up to three
weeks and had high levels of pre-existing P. falciparum specific antibodies transcribed only a
single or very few dominant group B and B/C var genes. In one asymptomatic individual the
var gene expression dynamics could be monitored over six parasite replication cycles. This
demonstrated for the first time in vivo a shift in the dominant var gene transcripts in the para-
site population of an infected individual.
Results
P. falciparum infection kinetics of the volunteers
For this CHMI study [39] with direct venous inoculation (DVI) of PfSPZ Challenge, lifelong
malaria-exposed individuals were recruited in Lambare´ne´, Gabon, where the prevalence of
asymptomatic P. falciparum parasitemia is high due to the perennial transmission of malaria,
but the local adult population rarely, if ever, develops severe malaria and has a low frequency
of symptomatic, mild infections [40]. African adults were screened for hemoglobin genotype
and 9 sickle cell trait carriers (HbAS) as well as 11 volunteers with hemoglobin HbAA were
included (S1 Table). Five European adults without malaria history were also recruited as
malaria-naïve controls (mean age: 26.8, range: 24.3–28.8). They were treated when the first
thick blood smear was positive, a time when first malaria symptoms occurred in malaria-naïve
volunteers [39, 41]. In malaria-experienced adults, treatment was commenced either once the
thick blood smear was positive and symptoms that could be attributed to malaria were present,
or if volunteers developed a parasitemia above 1,000 parasites/μl, or at the end of the study on
day 28 post infection if no parasitemia developed [39]. Clinical outcome and safety data of the
clinical studies have been published previously [39, 41].
Malaria-exposed adults were classified into the three groups, ‘controller’ (mean age: 22.9,
range: 19.1–25.9), ‘non-controller’ (mean age: 21.8, range: 19.0–24.6) or ‘clearer’ (mean age:
21.5, range: 18.6–26.6), according to their susceptibility to infection during CHMI with PfSPZ
Challenge (Fig 1A, S1 Table). Volunteers who remained negative in the thick blood smear
until the end of the study on day 28 post infection, were classified as ‘clearer’ (n = 8; L1-002,
L1-007, L1-009, L1-011, L1-013, L1-016, L1-021, L1-022). Volunteers who became positive
after day 17 (range: 17–25) and retained low-density peak parasitemia of 14–400 parasites/μl
(median: 129.5) until the day of treatment, mostly without symptoms, were classified as ‘con-
troller’ (n = 6; L1-003, L1-010, L1-018, L1-023, L1-026, L1-028). These patients were treated
var expression in semi-immune volunteers
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between day 23–28 (median: 28). In comparison, volunteers who became parasite positive
between day 13–18 (median: 15.5) and showed a exponential rise in parasitemia with median
parasite counts of 1,256 parasites/μl (range: 3–5,070) at treatment initiation between day 16–
19 (median: 17) were classified as ‘non-controller’ (n = 6; L1-005, L1-006, L1-008, L1-017, L1-
019, L1-020). Seven HbAS carriers fell into the group of ‘clearer’ or ‘controller’ whereas two
HbAS volunteers, L1-005 and L1-017, were treated on day 18 and 19 post infection, respec-
tively, due to malaria attributed symptoms and positive thick blood smear and were accord-
ingly classified as ‘non-controller’. Malaria-naïve European adults (L1-001, L1-014, L1-015,
L1-024, L1-025) reached 2–9 parasites/μl (median: 5) between day 12 and 14 (median: 12) post
infection [39]. This is comparable to 2.5–54 parasites/μl (median: 7.5) between day 10.5–15
(median: 11.5) post infection observed with 18 malaria-naïve volunteers infected with an
increasing dose of PfSPZ Challenge during our previous trial in Tu¨bingen [37, 41] (Fig 1A).
Characterization of volunteer immune status at the start of the trial
To assess the level of anti-malarial immunity of the participants at the beginning of the study,
plasma samples were screened in a Luminex assay for their reactivity to a panel of P. falcipa-
rum proteins (Fig 1B; S1 and S2 Figs; S2 and S3 Tables). This panel comprised 19 different
EPCR-binding CIDRα1 domains, 12 CD36-binding CIDRα2–6 domains, and three CIDRδ1
domains from different parasite strains, as well as a single CIDRγ3 domain to analyze reactivity
to PfEMP1 molecules with different binding capacities (S2 Table). Several conserved and
immunogenic P. falciparum antigens (apical membrane antigen 1 (AMA1), merozoite surface
protein 1 (MSP1) and circumsporozoite protein (CSP)) as well as tetanus toxin were also
included. MFI (mean fluorescence intensity) values representing IgG levels to these proteins
Fig 1. Subgrouping of volunteers into malaria-naïve, ‘non-controller’, ‘controller’ and ‘clearer’. (A) Parasite counts determined by thick blood smear. Parasite counts
(parasites/μl) during the course of the CHMI trial determined by thick blood smear until treatment was initiated. Parasite replication occurs exponentially in malaria-
naïve controls (n = 5), which were treated immediately after first detection of parasites in the peripheral blood. Lifelong malaria-exposed volunteers were grouped
according to their ability to control parasite growth. ‘Non-controller’ (n = 6) showed a delayed exponential parasite replication, ‘controller’ (n = 6) were able to control
the parasitemia below 100 parasites/μl and ‘clearer’ (n = 8) were able to eliminate injected parasites and thick blood smears were never positive for parasites. (B)
Reactivity of volunteer sera with PfEMP1-specific antigens and control proteins at the start of the trial. The reactivity of sera from the different volunteer groups to
EPCR-binding CIDRα1 domains (n = 19), CD36-binding CIDRα2–6 domains (n = 12) and CIDR domains with unknown binding phenotype (CIDRγ3: n = 1, CIDRδ1:
n = 3) was assessed by luminex assay. The P. falciparum antigens AMA1, MSP1, CSP known to induce an antibody response in humans served as positive controls.
Furthermore, beads coated with VAR2CSA (VAR2), tetanus toxin (TetTox) and bovine serum albumin (BSA) were used as additional controls. Individual mean
fluorescence intensities (MFI) are shown in a box plot extending from the 25th to the 75th percentiles with a line at the median. Number of sera analyzed from the
different volunteer groups were ‘malaria-naïve’ n = 5, ‘non-controller’ n = 5, ‘controller’ n = 6 and ‘clearer’ n = 8.
https://doi.org/10.1371/journal.ppat.1007906.g001
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are presented in Fig 1B. Malaria-naïve European volunteers showed a high recognition of teta-
nus toxin due to vaccination, but very low reactivity to the malaria antigens.
Using the average plus two standard deviations of the malaria-naïve IgG levels for each pro-
tein as cutoff for seropositivity, the breadth of recognition of the CIDRα1, CIDRα2–6 and
CIDRδ/γ domains was calculated. This showed that both CIDRα1 and CIDRα2–6 domains
but not CIDRδ/γ domains were more frequently recognized by ‘controllers’ and ‘clearers’ than
by ‘non-controllers’ (Mann-Whitney U test, p = 0.0232 for CIDRα1; p = 0.0128 for CIDRα2–
6; p = 0.08264 for CIDRδ/γ) (S3 Table).
IgG levels normalized to a positive control standard curve were used to assess IgG level dif-
ferences between volunteer groups. IgG levels to CIDRα1 and CIDRα2–6 domains but not
CIDRδ, CIDRγ or any of the merozoite antigens tested, were higher in the ‘controllers’ and
‘clearers’ compared to the ‘non-controllers’ (Mann-Whitney U test; p = 0.0139 for CIDRα1
and p = 0.0105 for CIDRα2–6, respectively). IgG levels to sporozoite antigen CSP was higher
in volunteers who were able to clear the infection compared to the group of ‘non-controllers’.
Altogether, these data suggest that the ability of these volunteers to control the PfSPZ infection
was associated with a broader and higher level of IgG reactivity against PfEMP1.
Impact of immunity on var gene expression in P. falciparum
To understand how anti-malarial immunity influences var gene expression in the parasite pop-
ulation we analyzed the var transcript patterns in parasites infecting semi-immune adults and
naïve volunteers. Parasites’ var transcript abundance profiles were determined from 10 lifelong
malaria-exposed adults, five from the group of ‘non-controller’ (L1-006, L1-008, L1-017, L1-
019, L1-020) and ‘controller’ (L1-010, L1-018, L1-023, L1-026, L1-028), respectively, at the day
of treatment (Fig 2, S4 Table). No expression data could be generated from the five infected
malaria-naïve individuals due to the low parasitemias and the small sample volume harvested
during the trial. Therefore, we included our previous data set from malaria-naïve volunteers
for the analysis [37] (Fig 2).
The ‘non-controller’ samples showed broad expression of many B-type var genes, although
most abundant variants slightly differed between each volunteer (Fig 2). Transcripts coding
for A- and C-type PfEMP1 proteins as well as the conserved proteins VAR2CSA, VAR1 and
VAR3 were rarely detected (Fig 2, Fig 3A). In contrast, parasites from all five volunteers
assigned as ‘controller’ exhibited unique expression patterns with a single or very few highly
expressed var gene variants (Fig 2). Variants expressed at the highest level were PF10_0406/
PF3D7_1041300 (L1-010), PFE0005w/PF3D7_0500100 and PFA0765c/PF3D7_0115700 (L1-
018), PFI0005w/PF3D7_0900100 and PFL1955w/PF3D7_1240400 (L1-028), MAL7P1.55/
PF3D7_0712800 (L1-023) and var2csa (L1-026). With exception of var2csa, all genes belong to
the B- or B/C-var type and are only moderately expressed in parasites from malaria-naïve vol-
unteers and ‘non-controllers’ (Fig 3A). The ‘non-controller’ expression profiles clustered
together with samples from malaria-naïve volunteers and away from the ‘controllers’, indicat-
ing that the PfEMP1-specific immunity observed in ‘controllers’ has a significant impact on
the var expression profile on the population level (Fig 2). To summarize the findings, a princi-
pal component analysis (PCA) was conducted considering var gene expression data, MFI val-
ues obtained by luminex, parasite counts at the day of treatment and number of days until
parasite positivity. This PCA confirms the separation of the volunteer samples into the two
groups of ‘non-controller’ and ‘controller’ by PC1 (S3 Fig).
Interestingly, A-type var transcripts, particularly those encoding the EPCR-binding variant
PFD0020c/PF3D7_0400400, were found to be among the most abundant in samples from
malaria-naïve volunteers but were rarely detectable in samples from ‘non-controllers’ and
var expression in semi-immune volunteers
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Fig 2. Patterns of var transcript level in malaria-naïve [37] and lifelong malaria-exposed adults sampled prior treatment.
Heat map showing the individual var transcript profiles for all volunteer samples taken immediately before treatment was
initiated. To correct for individual differences in the overall var transcript levels, the level for each var gene was normalized
against total var transcript level in each sample. Hierarchical cluster analysis confirms that the subgroups of malaria-naïve
(mn), ‘non-controller’ (nc) & ‘controller’ (c) volunteers are characterized by different var transcript patterns. Volunteers IDs of
malaria-naïve samples according to [37]. Annotations of var gene variants are indicated on the left side, var gene group
affiliations are indicated by the color code with A-type var genes in red, the subfamilies var3 and var1 in orange and dark red,
B/A genes in purple, B-type genes in blue, B/C genes in turquoise, group C genes are colored in green and the var2csa gene
(group E) is shown in yellow.
https://doi.org/10.1371/journal.ppat.1007906.g002
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absent in parasites infecting the group of ‘controllers’ (Fig 2, Fig 3A). Other variants detected
at high levels more frequently in malaria-naïve individuals included the B-variants MAL6P1.1/
PF3D7_0632800 and PFI1830c/PF3D7_0937800 as well as the B/A-variant MAL6P1.4/
PF3D7_0632500. A comparison on var gene group level showed that transcripts of A-type var
genes (excluding var1 and var3 genes) were responsible for 8.8% of the total var transcripts in
Fig 3. Impact of semi-immunity on parasites’ var gene expression. (A) Ranking of var genes according to transcript level detected in samples from malaria-
naïve volunteers and lifelong malaria-exposed adults classified as ‘non-controller’ and ‘controller’ at the last time point sampled prior to treatment. The
median var transcript level relative to the sbp1 transcript level with IQR is shown for all malaria-naïve (n = 18), ‘non-controller’ (n = 5) and ‘controller’ (n = 5)
volunteer samples. Expression values for genes of the different var groups are presented in red (group A), orange (subfamily var3), dark red (subfamily var1),
purple (group B/A), blue (group B), turquoise (group B/C), green (group C) and yellow (group E). (B) Proportion of var transcripts according to var group
affiliation in parasites from malaria-naïve, ‘non-controller’ & ‘controller’. For comparison, genomic proportions of genes classified into the different var gene
groups are shown. Proportions of var3 and var1 type gene expression are not indicated separately, because numbers were below 0.3% in all volunteer groups.
(C) Comparison of the levels of var transcripts encoding for EPCR-binding CIDRα1 (‘EPCR’), CD36-binding CIDRα2–6 (‘CD36’) or CIDRγ/δ (‘other group
A’) domains in the different volunteer groups. Shown are expression values (%) for each var gene normalized against total var transcript level in each
volunteer sample and plotted showing the median and the IQR. Gene expression of the different gene sets varied significantly between volunteer groups
(Mann Whitney U test, � = p<0.05, �� = p<0.01, ��� = p<0.0001).
https://doi.org/10.1371/journal.ppat.1007906.g003
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malaria-naïve volunteers, but accounted only for 2.4% (‘non-controller’) and 1.0% (‘control-
ler’) of the total var transcripts in parasites from volunteers with prior exposure to malaria (Fig
3B). Transcripts from two B/C-type var variants and var2csa were found at very high levels in
parasites from volunteers able to control the infection. Therefore, the overall frequency of
these two var gene groups was significantly elevated in the group of ‘controller’ (Fig 3B).
We next wanted to investigate whether parasites from the different groups of volunteers
showed preferential expression of var genes associated with particular binding phenotypes.
Therefore, we analyzed the levels of transcripts encoding CD36 binding PfEMP1 (most B- and
all C-type var genes), EPCR-binding PfEMP1 (A-type variants PF11_0521/PF3D7_1150400,
PFD0020c/PF3D7_0400400 and PFD1235w/PF3D7_0425800 as well as the B/A-variants
MAL6P1.316/PF3D7_0600200 and PF08_0140/PF3D7_0800300) and other A-type var genes
(A-type PfEMP1 proteins PF11_0008/PF3D7_1100200, PF13_0003/PF3D7_1300300,
PF08_0141/PF3D7_0800200) (Fig 3C). Levels of transcripts encoding EPCR-binding PfEMP1
relative to the sbp1 (skeleton binding protein 1) control gene were substantially higher in
malaria-naïve than in lifelong malaria-exposed adults (Mann-Whitney U test, p<0.001) with
median expression of 4.0 (range: 0.0–24.2) in the malaria-naïve group, 0.1 (range: 0.0–7.5) for
‘non-controller’ and 0.0 (range: 0–15.8) for ‘controller’. This trend was also observed for other
A-type variants not predicted to bind EPCR and possibly associated with rosetting (Mann-
Whitney U test, p<0.001) with a median of 3.6 (range: 0–32.8) for malaria-naïve samples and
median values of 0.1 (range: 0–4.4) and 0.0 (range: 0–1.6) for samples from ‘non-controller’
and ‘controller’ (Fig 3C). Differences in median transcript levels were also observed for genes
encoding CD36-binding PfEMP1 between volunteers with different immune status. While
malaria-naïve adults exhibited the highest transcript levels, the range of the values for ‘control-
ler’ samples (median 0.0, range: 0–63.5) was wider than in both other groups (malaria-naïve:
median 2.9, range: 0–30.1; ‘non-controller’: median 0.5, range: 0–44.1) due to a predominant
expression of single individual CD36-binding variants in some of these samples.
In conclusion, var types previously associated with the potential to develop severe malaria
were more abundantly expressed in malaria-naïve individuals than in malaria-exposed volun-
teers. Antibodies recognizing these PfEMP1 variants are prevalent in malaria-exposed individ-
uals and likely provide the driving force which selects the parasite population against
expression of these variants.
Var transcript profile changes in vivo
For several volunteers who maintained low parasitemia without malaria symptoms, we were
able to collect consecutive samples over up to six replication cycles, allowing us to monitor
changes in var profiles over time in vivo. Samples from two consecutive time points in vivo (1–
3 days apart) obtained from ‘non-controller’ (L1-006, L1-017, L1-019) or ‘controller’ (L1-010)
volunteers were highly correlated and showed only slight differences in their var gene expres-
sion profiles (ρ, Pearson’s correlation coefficient: L1-006: ρ = 0.91, L1-010: ρ = 0.99, L1-017: ρ
= 0.93, L1-019: ρ = 0.65) (S4 Fig). Similarly, parasites from ‘controller’ L1-028 stably expressed
PFI0005w/PF3D7_0900100 (B-type) and PFL1955w/PF3D7_1240400 (B/C-type) from day 23
to day 28 (5 days apart), when the study was terminated (ρ = 0.97–1.00) (Fig 4A). In contrast, a
major change was detected during the course of the infection in samples from ‘controller’ L1-
026 from who samples could be taken over 11 days. This particular volunteer was able to con-
trol the infection and maintain a parasitemia below 100 parasites/μl during the entire trial and
only slight changes in the parasite counts were observed (S1 Table). From day 17, when para-
sites were first detected in the blood, to day 23 post infection parasites predominantly
expressed three var gene variants: The B-type variant PFI0005w/PF3D7_0900100, the B/C-
var expression in semi-immune volunteers
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Fig 4. Var gene expression changes in vivo. (A, B) Monitoring of var gene expression over 3 or 6 parasite generations in
volunteers L1-028 (A) and L1-026 (B) from the group of ‘controller’. Upper heat maps show the var transcript patterns of samples
taken serially from volunteer L1-028 on day 13, 25 and 28 and from volunteer L1-026 on day 17, 19, 21, 23, 25 and 28 post
infection. Lower heat maps present Spearman’s rank correlation coefficient (ρ) between the different samples. In all samples from
L1-028 (A) the var transcript pattern was stable across the parasite replication cycles analyzed also indicated by the heat map
showing the Spearman’s rank correlation coefficient between the different samples, which are all close to 1. For L1-026 (B) a major
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type variant PFL1955w/PF3D7_1240400 and the var2csa gene PFL0030c/PF3D7_1200600
(group E) (Fig 4B). On day 25 post infection the transcript abundances of another B-type vari-
ant (PFL0935c/PF3D7_1219300) started to increase and, at the same time, levels of the previ-
ously expressed B- and B/C-type variants dropped. This pattern was confirmed on day 28 post
infection, when transcripts from three C-type variants (PFD1015c/PF3D7_0421300,
PFL1960w/PF3D7_1240600, PF07_0051/PF3D7_0712600) were also elevated (Fig 4B). Inter-
estingly, expression of the pregnancy-associated var2csa gene increased continuously during
the course of the infection and, in parallel, expression of sbp1 coding for a Maurer’s clefts pro-
tein known to be important for PfEMP1 trafficking to the infected erythrocyte surface was
drastically reduced (S5 Fig). In line with these observations, samples from day 17 and 28 post
infection showed only weak correlation with each other (ρ = 0.29) (Fig 4B).
Acquisition of PfEMP1-specific antibodies during and after CHMI
To understand how CHMI affected PfEMP1-specific antibody acquisition, antibody recogni-
tion of PfEMP1 domains was compared before and after infection (S3 Table, S5 Table, S2 Fig).
In general, malaria-naïve volunteers and ‘non-controllers’ showed higher reactivity to most
antigens tested on day 28 post infection compared to pre-infection (day -1). This was also the
case for a few of the ‘controllers’ and ‘clearers’. This may be due to a general unspecific poly-
clonal activation of the B cell response as previously observed to occur during malaria and
other protozoan infections [42–46]. In attempt to identify antigen specific seroconversion,
antigens to which the change in IgG response was particularly high (defined as outliners above
1.5x interquartile range of the fold changes in IgG reactivity within each volunteer) was deter-
mined (S5 Table). This showed that all malaria-naïve volunteers but only few other volunteers
seroconverted to MSP1. Also malaria-naïve and ‘non-controller’ volunteers overall appeared
to seroconverted more frequently to other malaria antigens compared to ‘controllers’, however
the data was insufficient to reach statistical significance.
Discussion
Despite improvements in our knowledge over the past few years, quantitative data on var
expression patterns and transcription dynamics during infection of the human host is still
sparse. This lack hampers our understanding of parasite immune evasion strategies such as
antigenic variation and sequestration, neither of which can be effectively simulated in vitro.
Previous analyses of ex vivo field isolate samples i) are mostly semi-quantitative and biased by
the tremendous genetic variability of VSAs [21–23, 47–50], ii) are restricted to investigations
of subsets of var genes such as promotor-based var subgroups or subgroups based on the
PfEMP1 domain cassettes (DC) architecture [4, 9, 19, 20, 29, 30, 51–53] and iii) do not provide
quantitative analyses of within-host expression dynamics. To overcome these problems, we
analyzed ex vivo samples from CHMI studies with PfSPZ Challenge generated from an NF54
cell bank. NF54 has previously been reported to consist primarily of 3D7 but an additional sib-
ling parasite called E5 has been detected in some NF54 laboratory stocks [54, 55]. However, E5
is not present in the NF54 that was used to generate PfSPZ indicating that it is isogenic with
the fully sequenced 3D7 genome strain. This enabled us to monitor RNA expression in the
human host with a high-sensitivity qPCR approach for each individual var gene variant pres-
ent in the genome of the parasite and also provide quantitative data on var gene expression
change of var gene expression during the time period analyzed was observed. Day of sampling is indicated as day post infection.
The color scales above the expression heat map indicate the relative expression level with red representing values�40%, values of
0 are colored in yellow.
https://doi.org/10.1371/journal.ppat.1007906.g004
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dynamics during the course of the infection for the first time. This study also expands our pre-
vious study characterizing in vivo var expression patterns of parasite populations in volunteers
without previous malaria exposure [37] by analyzing expression profiles in lifelong malaria-
exposed African adults. We report that parasites in malaria-naïve volunteers replicate expo-
nentially and express a broad var gene repertoire of mostly A- and B-type variants early after
transition from hepatic to blood stage. In African volunteers termed ‘non-controller’, however,
parasites show a delayed exponential parasite growth relative to naïve volunteers infected in
parallel. This delay may be due to the activation of memory responses that might be reflected
by the measurable level of anti-malarial antibodies at the onset of the study. Similar to malaria-
naïve volunteers infected in a previous trial [37], the var gene expression profile in these volun-
teers was rather broad and dominated by B-type variants, however, A-type var genes were
expressed less frequently than in naïve individuals. In contrast, volunteers able to control para-
site growth and maintain a low parasitemia (‘controller’) appeared to have already acquired
higher levels of functional antibodies against PfEMP1 and other antigens during previous
infections. This might result in a clonal selection of parasites within the host leading to the
expression of only a single or very few var gene variants of B- or B/C-type. In comparison to
parasites from malaria-naïve volunteers, parasites from lifelong malaria-exposed adults show
more individual var gene expression patterns with a significant reduction of A-type variants.
Similarly, genes coding for EPCR-binding PfEMP1 variants were expressed less frequently in
parasites from lifelong malaria-exposed Africans than in parasites infecting malaria-naïve vol-
unteers. Particularly PFD0020c, an A-type var gene coding for an EPCR-binding PfEMP1, was
highly expressed in parasites from malaria-naïve volunteers, but transcripts were absent in par-
asites from almost all African volunteers. Interestingly, it has been observed that expression of
group A PfEMP1 is correlated with severe childhood malaria and immunity against these vari-
ants is rapidly acquired early in life before antibodies to other PfEMP1 variants in malaria-
exposed individuals [22, 32, 33, 35]. This may be due to a higher immunogenicity of A-type
PfEMP1s or their higher degree of conservation between parasite strains [22, 34–36]. Further-
more, a recent CHMI study in which Kenyan adults with varying natural exposure were
infected intramuscularly with the same inoculum (PfSPZ Challenge) showed an association
between the expression of var gene group A and DC8-like PfEMP1 with low levels of antibod-
ies to infected erythrocytes [52]. Expression of var genes coding for a EPCR-binding
CIDRα1.1 domain were also associated with a higher parasite multiplication rate independent
of the prior exposure to malaria parasites. This could indicate that parasites able to stick to the
endothelium via EPCR may have a lower splenic clearance rate than parasites with other bind-
ing phenotypes and, as a result, are able to expand more rapidly [52]. Overall, expression of
var group A and genes coding for PfEMP1 with EPCR-binding CIDRα1 subtypes seems to
occur more frequently in malaria-naïve individuals and in severe malaria cases [20, 51] and to
increase with disease severity [29, 53]. One explanation for this higher expression of A-type
and EPCR-binding variants could be an intrinsic expression program of the parasites when
entering the blood phase. Additionally, more effective cytoadhesion and lower splenic clear-
ance could explain preferential expression of A-type and EPCR binding variants on a popula-
tion level.
Parasite populations from ‘controller’ volunteers with higher antibody levels against
PfEMP1 domains transcribed only a single or two B or B/C-type var variants, which were
expressed at moderate levels in NF54 parasites early after liver release in malaria-naïve hosts.
Presumably, each of these B or B/C-type variants represents a gap in the antibody repertoire of
the infected individual. This is supported by the fact that the variants differ between almost all
parasite populations infecting ‘controller’. Only parasites from L1-026 and L1-028 highly
express the same two variants PFI0005w/PF3D7_0900100 and PFL1955w/PF3D7_1240400,
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but expression was stable between day 23 and 28 post infection in volunteer L1-028 and
switched on day 25 post infection in L-026. Both proteins have the typical four domain struc-
ture of B-type PfEMP1s and share most of their extracellular exposed domain subtypes: They
possess an NTS domain of B3 type, a DBLα0.16, a CIDR3.4 as well as a DBLδ1 domain and
diverge only in their C-terminal CIDR domain where PFI0005w/PF3D7_0900100 has a
CIDRγ12 and PFL1955w/PF3D7_1240400 a CIDRβ1 domain. This implies that both proteins
may share some structural or binding characteristics and may fill the same gap in the antibody
repertoire.
We postulate that the different transcript levels for each var variant observed in non-
immune hosts reflects the probability of each var gene to be turned on by individual parasites
in the population after liver release [37] and the effect of receptor binding favoring the expan-
sion of parasite populations transcribing specific binding phenotypes [56]. However, in semi-
immune hosts parasites expressing PfEMP1 variants similar to variants from previous infec-
tions are eliminated due to a memory response. In support of this ‘gap in the (antibody) wall’
theory, former studies of human P. falciparum infections have also indicated that acquisition
of VSA-specific immunity can shape the VSA expression pattern, probably by gradually nar-
rowing the repertoire of VSAs compatible with parasite survival in the semi-immune host [57–
59]. This is associated with a decrease in the virulence of the infection and therefore, acquisi-
tion of VSA-specific antibodies appears to be central to acquisition of protective immunity in
humans [60]. Hence, antibody levels against certain PfEMP1 CIDR domain types pre-infection
are to some extent predictive of the course of the infection as well as of the parasites’ var gene
expression patterns. Identification of antigen specific IgG responses to CHMI was difficult to
elucidate in part due to a generally increased IgG level to both malaria and control antigens.
CHMI may induce unspecific B-cell activation [42–46], but the mechanism for this phenome-
non is unknown. Most evident was an acquisition of MSP1 antibodies in malaria-naïve volun-
teers, but also antibody responses to a few heterologous PfEMP1 antigens were observed.
Infection of malaria-naïve and semi-immune adults with P. falciparum under controlled
experimental setting enables monitoring of the within-host expression dynamics longitudi-
nally during the course of infections. To address this point, serially taken blood samples from
six volunteers were analyzed in this study. The data provide the first quantitative description
of an in vivo antigenic variation event on the level of transcription during infection with a sin-
gle P. falciparum genotype. Although this was only observed in a single volunteer infected
until the study was terminated by treatment, future CHMI studies with semi-immune volun-
teers will contribute more examples, possibly enabling the deduction of general strategies used
by the parasite to escape from the human immune system and the calculation of the frequency
of var gene switching directly from in vivo data. During the short time window analyzed, we
could not discriminate between switching on transcriptional level initiated by the parasite and
a host antibody-based selection against parasites expressing PfEMP1 variants. Several studies
have indicated that antigenic variation occurs in response to the appearance of anti-VSA anti-
bodies during the course of the infection in nonhuman primate infections [61–64] as well as in
a P. falciparum-infected patient [60]. Beyond that, Barnwell et al. have shown that P. knowlesi
switches SICAvar variants in animals having specific antibodies, whereas the same parasite
clones did not switch phenotype in naïve animals [61]. Depending on the infected individual
and the antigen load, functional antibodies tend to appear 7–10 days after recognition of the
antigen in the peripheral blood circulation, which would fit with the time frame in which the
var gene transcriptional change occurred in L1-026, 7 days after positive indication by thick
blood smear (day 25 after infection). To verify this, acquisition of specific antibodies against
the PfEMP1 variants PFI0005w/PF3D7_0900100 and PFL1955w/PF3D7_1240400 during the
course of the infection should be measured, which is complicated by the fact that the exact
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antibody epitope is unknown and the immune response against correctly folded full-length
extracellular protein regions with a size of about 200 kDa have to be analyzed. PFI0005w/
PF3D7_0900100 and PFL1955w/PF3D7_1240400 as well as the variant PFL0935c/
PF3D7_1219300 turned on at day 25 post infection share the CIDRα3.4 domain predicted to
bind CD36 which was not represented in our luminex assay. Maybe all three PfEMP1 variants
share binding characteristics but differ in their epitopes recognized by the B-cell receptor and
the resulting antibodies.
The observed continuous increase of var2csa expression supports the hypothesis that
var2csa may act as a switching intermediate as suggested earlier [65, 66]. Ukaegbu and col-
leagues have shown that the highly conserved var2csa gene has the lowest threshold for activa-
tion after destabilization of var specific chromatin and could occupy this unique intermediate
position within the var switching hierarchy [66]. Alternatively, var2csa could be a switch off
button for PfEMP1 display. Indeed, it has recently been suggested by a study analyzing
PfEMP1 expression in a population of Kenyan children that parasites from chronic infections
may express less PfEMP1 [67]. This gene can be transcriptionally turned on while being trans-
lationally repressed, a unique feature of var2csa amongst members of the var family, which
would cause a shutdown of PfEMP1. In line with that, transcripts from this gene have fre-
quently been observed in non-pregnant individuals including men indicating that this gene
has an alternative or additional function than ‘just’ being the ligand in pregnancy-associated
malaria [68–70]. Additionally, we found that the transcript level of sbp1 dropped during infec-
tion in L1-026. The Maurer’s cleft located protein SBP1 is generally implicated in protein
export, has been shown to be essential for the display of PfEMP1 on the surface of the IE [71],
and was also down-regulated during severe malaria [72]. Maybe, parasites transcribing but not
translating var2csa into a functional protein are able to survive in the host without surface-dis-
played PfEMP1 and simultaneously down-regulate the gene expression of other components
involved in PfEMP1 export like the recently described novel protein complex EPIC (exported
protein-interacting complex) [73]. However, further data are necessary to prove this
hypothesis.
In summary, our data suggest that the parasite population exiting the liver is reset to express
predominantly subtelomeric A- and, especially, B-type var genes, which may involve epige-
netic mechanisms that specifically act on subtelomeric chromatin. In naïve individuals, para-
sites expressing more conserved variants with strong binding properties (e.g. to EPCR) may
have a selective advantage and thus predominate in naïve infections, leading to the observed
frequency of severe infections in young children. Due to the acquisition of antibodies during
first infections parasites expressing these more conserved A-type variants would be cleared
early in subsequent infections, resulting in the expansion of parasites expressing less conserved
variants. Further acquired immunity to the more diverse variants would progressively narrow
the repertoire of parasite clones that are able to establish patent and virulent infections in indi-
viduals who have been exposed to several previous malaria episodes, consistent with our obser-
vation that volunteers that were able to control parasitemia showed distinct and small
repertoires of expressed var genes and took longer to have positive blood smears. Taken
together, our study provides unique and novel insight into parasite mechanisms to establish an
infection after transmission.
Conclusion
Our results experimentally support several previously raised ideas about var gene expression
in P. falciparum in the context of varying degrees of semi-immunity. First, antibodies against
variants highly expressed in malaria-naïve hosts including A-type and EPCR-binding variants
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are developed first. Second, greater immunity to PfEMP1 is associated with protection from
infection. Third, pre-existing immunity in the host shapes the var expression profile of the
infecting parasite population leading to expression of a single or very few variants. Moreover, a
change in parasites’ var expression was demonstrated for the first time in vivo in a window of
time consistent with the development of a specific immune response.
Materials and methods
Ethics approval and consent to participate
The Gabonese national ethics committee (Comite´ National d’Ethique de la Recherche)
approved the study conducted in Lambare´ne´, which was also filed under an US FDA Investiga-
tional New Drug application (IND). Safety of participants was supervised by an independent
safety review committee. The study is registered with ClinicalTrials.gov, number
NCT02237586 [39]. The study was conducted according to the principles of the Declaration of
Helsinki in its 6th revision as well as International Conference on Harmonization–Good Clini-
cal Practice (ICH-GCP) guidelines. All volunteers, aged 18 to 30 years, provided written
informed consent and understanding of the study and procedures was assessed with a quiz.
CHMI trials and blood sampling
CHMI with malaria-naïve controls and lifelong malaria-exposed African adults was conducted
in Lambare´ne´, a region with perennial transmission of malaria and semi-immunity against
severe malaria in adults. Volunteers were assessed by thick blood smear and PCR for parasite-
mia before CHMI. In addition, all volunteers were treated with an effective antimalarial with a
short half-live for 5 days in order to remove any residual parasites from the circulation [39].
During the clinical trial, healthy volunteers were infected by DVI with 3,200 aseptic, purified,
cryopreserved NF54 sporozoites (PfSPZ Challenge) provided by Sanaria Inc., USA. The NF54
isolate is composed primarily of 3D7, the malaria genome reference strain, but an additional
NF54 clone called “E5” has also been identified [54, 55]. To assess if E5 was present in the
NF54 Sanaria strain, E5 var gene specific PCR was performed on DNA of the working cell
bank SAN02-073009 NF54 Sanaria strain [38]. No E5-specific var gene fragments were ampli-
fied indicating that NF54 Sanaria is isogenic with 3D7. Blood samples for thick blood smear
were taken daily from the onset of potential merozoite release at day 5 post infection and for
var transcription profiling according to S1 Table. Briefly, 0.5–1 ml of blood pellet was recov-
ered from Heparin or BD Vacutainer CPT tubes, washed with 5 ml of RPMI or 1xPBS and
centrifuged for 5 min at 700 g. Five volumes of Trizol or Trifast Reagent (Peqlab) were added
to the erythrocyte pellet and frozen at -80˚C. If possible, plasma samples were taken the day
before infection (-1), and on day 7, 13, 19, and 28 post infection. Non-immune volunteers
received treatment with artemether-lumefantrine once their thick blood smear became para-
site positive by microscopy. In African adults, treatment was administered once thick blood
smear was positive and any symptoms that could be attributed to malaria were present. Volun-
teers with a parasitemia above 1,000 parasites/μL were treated irrespective of symptoms. All
volunteers without parasitemia or remaining at low-density parasitemia without symptoms
were treated on day 28 post infection [39].
RNA purification and cDNA synthesis
RNeasy Mini (Qiagen) with on-column DNase I (Qiagen) treatment was used for RNA purifi-
cation. Absence of gDNA was checked for each sample using 50 ng RNA and the sbp1 primer
set. cDNA synthesis was performed as described previously [37].
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Quantitative real-time PCR
The LightCycler 480 (Roche) was used for quantitative real-time PCR analysis using the pro-
vided software version 1.5. cDNA template was mixed with QuantiTect SYBR Green PCR
reagent (Qiagen) and 0.3 μM sense and antisense primer in a final volume of 10 μl. Reactions
were incubated at 95˚C for 15 min, then subjected to 40 cycles of 95˚C for 15 s and 60˚C for 1
min and a subsequent melting step (60–95˚C). The specificity of each primer pair was con-
firmed after each qPCR run by dissociation curve analysis. Ct calculation was done using the
fit points analysis method provided by the software. Expression of sbp1 (PFE0065w/
PF3D7_0501300) was used for normalization and Ct values obtained by analysis of 2.5 ng
gDNA from pre-mosquito parasites were used for calibration. Relative quantification of the
NF54 var repertoire by 2-ΔΔCt analysis was performed using previously described primer sets
as well as 24 new primer sets (S6 Table) [37]. Furthermore, primer pairs targeting the house-
keeping genes fructose-bisphosphate aldolase (PF14_0425/PF3D7_1444800) and arginyl-tRNA
synthetase (PFL0900c/PF3D7_1218600) were included (S6 Table). Relative expression data
(RELATEXP) were corrected for amplification efficiency of each primer pair, which was deter-
mined by dilution of a single gDNA from NF54 over 5–6 logs of concentration (S6 Table).
Only samples with a Ct value below 30 for the two housekeeping controls fructose-bisphosphate
aldolase and arginyl-tRNA synthetase were included, which was shown to be a useful standard
for var gene transcript analysis in patient samples [37, 51]. For further control, Ct values of
both housekeeping genes as well as sbp1 (normalizer) were compared between the volunteer
groups and were shown to be similar (S6 Fig). Data from our previous study with malaria-
naïve volunteers were transformed so that the relative expression value was divided by two for
three of the formerly used primer pairs because they amplified two var genes (PFD0630c/
PF3D7_0412900 & PFD0635c/PF3D7_0413100, PFL1955w/PF3D7_1240400 & PFL1970w/
PF3D7_1240900, PFD0995c/PF3D7_0420700 & PFD1000c/PF3D7_0420900).
Heat maps are used to display var gene expression on individual level. For var genes the rel-
ative expression per individual (i.e., percent gene expressed) was used and variants without
detected Ct-values (i.e., >40 cycles) were set to 0. A cut-off of 40% was used to limit maximum
expression levels in the var gene expression heat maps. Hierarchical clustering, with the
Euclidian distance using complete linkage method, was applied for var gene expression in the
different volunteers and the results are displayed in a dendrogram. RELATEXP distributions
for var genes associated with particular binding phenotypes over the different volunteer
groups are plotted showing the median and the interquartile range (IQR) and the non-
parametric Mann-Whitney U test was applied to calculate ρ-values on distributions differences
between volunteer groups. Pearson correlation coefficient (ρ) along with the 95%-confidence
interval was calculated to measure linear correlation between relative expressions in individu-
als measured on different days post infection. Pearson correlation coefficients on the associa-
tion between gene expression generations were calculated and displayed using heat maps. All
analysis and graphics were done using the base package of R version 3.4.0.
Luminex assay
35 recombinant HIS-tagged CIDR domains (S2 Table) were expressed in Drosophila Sf9 cells,
and purified by nickel affinity chromatography as previously described [7, 10, 33]. Total IgG
levels against these proteins were measured using a multiplex luminex assay, as previously
described [74] with minor modifications. Briefly, plasma samples were diluted 1:80 in Assay
Buffer E (ABE: 0.1% BSA, 0.05% Tween-20 in PBS, pH7.4). In ABE, a ten point, two-fold dilu-
tion of pooled positive plasma starting with a dilution of 1:40 was carried out. 50 μl of beads
and 50 μl of diluted plasma were added to 96-well microtiter plates (MSBVS 1210, Millipore,
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USA) pre-wetted with ABE. 50 μl of phycoerythrin-conjugated Goat Anti-Human IgG (Jack-
son ImmunoResearch Laboratories), diluted 1:3500 was added and using the BioPlex100 sys-
tem, mean fluorescent intensities and antibody concentrations were measured. Using the
pooled positive plasma, a standard curve was generated with an arbitrary value of 1000 relative
units assigned to the highest concentration, and IgG concentrations were interpolated from
the curves to give normalized values as “observed concentrations” (obs conc).
Individual IgG responses of 5 malaria-naïve controls and 19 lifelong malaria-exposed indi-
viduals (‘non-controller’: n = 5, ‘controller’: n = 6, ‘protected’: n = 8) were measured. In total,
plasma samples from day -1 (prior to infection), day 7, 13, 19 and 28 post infection were
screened for individual recognition of 19 different CIDRα1, 12 CIDRα2–6, three CIDRδ1
domains and a single CIDRγ3 domain to have a widespread fishing net for antibodies reacting
with all main types of PfEMP1 variants, i.e. those mediating binding to EPCR, CD36 or other
unknown receptors (S2 Table). The merozoite antigens AMA1 and MSP1, the sporozoite pro-
tein CSP as well as tetanus toxin served as positive controls, VAR2CSA and BSA were used as
negative controls. Plasma from volunteer L1-020 (‘non-controller’, male) were excluded from
analysis due to an irregular high reactivity against almost all antigens tested at all time points
tested. To analyze the acquisition of antibodies during infection, the obs conc ratio between
day -1 before and day 28 after infection was calculated for all volunteers except L1-025 and L1-
028 for whom no day 28 sera were available.
Principal component analysis
Principal component analysis (PCA) transforms correlated measurements into a set of uncor-
related values (so called principal components) by summarizing covariance measured in dif-
ferent directions, hence simplifying the underlying data structure. The first component
accounts for most data variance, while the consecutive components summarise as much of the
remaining variance as possible. For our model var gene expression data, MFI values, parasite
counts at the day of treatment, and number days until positivity were used as standardized (N
[0,1]) measurements. Only data from ‘controller’ and ‘non-controller’ were considered. A scat-
terplot was drawn to show clustering of participants over the study data, where individual
scores of the first two principal components were plotted, which account for most data
variance.
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S5 Table. Change in IgG levels from day -1 to day 28. The median (first and third quartiles,
Q1 and Q3) of observed concentration fold changes across all antigens tested is listed, showing
a similar and general change in IgG responses to all antigens for each volunteer. To the right,
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S1 Fig. Volunteer antibody response against individual CIDR domains and controls prior
to infection (day -1). Heat map showing reactivity of patient plasma samples prior to infection
with PfSPZ challenge with different CIDR domain subtypes and control antigens indicated on
the left side. Mean fluorescence intensity (MFI) values obtained by luminex assay are shown
for each volunteer. Hierarchical clustering with the Euclidian distance using complete linkage
method reveals three major groups with different reactivity patterns. First group contains
plasma samples mostly from ‘non-controller’ characterized by a high response to AMA1 and
low to medium recognition of other antigens. Second group consisting primarily of malaria-
naïve samples shows very low reactivity with all antigens tested except tetanus toxin. The third
group is formed by plasma samples from ‘clearer’ and ‘controller’ having more antibodies
directed against AMA1 and MSP1 as well as CIDR domains.
(PDF)
S2 Fig. Mean fluorescence intensities (MFI) of all volunteer sera measured for all antigens
by luminex over time.
(PDF)
S3 Fig. Principal component analysis of ‘non-controller’ and ‘controller’ considering var
gene expression, luminex data and infection curves of the volunteers. The first two model
components summarized 33% and 21% of the data variance, respectively, highlighting high
diversity in the underlying data structure. The biplot shows that ‘controller’ and ‘non-control-
ler’ cluster along the first two principal components. They can be separated along the first prin-
cipal component and ‘controller’ also tend to have lower scores on component 2. However,
participant L1-026 (a ‘controller’) has the highest score on component 2, which is primarily
due to an individual gene expression pattern.
(PDF)
S4 Fig. Correlation analysis of samples from two serial parasite generations obtained from
volunteers L1-006, L1-010, L1-017 and L1-019. Ex vivo samples from two consecutive para-
site generations could be obtained from four volunteers. L1-006, L1-017 and L1-019 belong to
the group of ‘non-controller’, L1-010 to the ‘controller’ group. Expression data were normal-
ized on total var expression in each sample (%) and Spearman’s rank correlation coefficients
(ρ) indicate a stable var gene expression across the parasite replication cycles analyzed. Day of
sampling is indicated as day post infection. Var genes color-coded consistently with the main
figures: red (group A), orange (subfamily var3), dark red (subfamily var1), purple (group B/
A), blue (group B), turquoise (group B/C), green (group C) and yellow (group E).
(PDF)
S5 Fig. Quantification of sbp1 decrease and var2csa increase over time in volunteer L1-026
determined by qPCR. RELATEXP values for sbp1, var2csa and arginyl-tRNA synthetase
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normalized against the housekeeping gene fructose-bisphosphate aldolase.
(PDF)
S6 Fig. Comparison of Ct values obtained for the normalizer (sbp1) and the two house-
keeping genes fructose-bisphosphate aldolase and arginyl-tRNA synthetase in samples from
the different volunteer groups. No difference in median expression was observed for all
primer sets between the volunteer groups malaria-naïve, ‘non-controller’ and ‘controller’ in
regard of RNA content in the samples. Data are shown in box plots extending from the 25th to
the 75th percentiles with a line at the median.
(PDF)
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